Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.57 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264236 | 0.89 | RAPGEF4 (0.52) | STK17AAXLAPPRAPGEF4EGFR | |
| SCHEMBL265799 | 0.87 | STK17A (0.53) | STK17AAXLRAPGEF4EGFRGRM4 | |
| SCHEMBL30306442 | 0.87 | STK17A (0.53) | STK17AAXLRAPGEF4EGFRGRM4 | |
| SCHEMBL28480411 | 0.87 | STK17B (0.54) | STK17AAPPEGFRKDRGRM4 | |
| SCHEMBL2103491 | 0.87 | SYK (0.54) | STK17AAPPEGFRKDRGRM4 | |
| SCHEMBL265476 | 0.84 | PIK3CA (0.47) | STK17AAXLEGFRKDRGRM4 | |
| SCHEMBL264886 | 0.84 | GRM4 (0.48) | STK17AAXLEGFRIDO1TDO2 | |
| SCHEMBL266579 | 0.82 | STK17A (0.52) | STK17AEGFRKDRAURKA | |
| SCHEMBL654379 | 0.81 | SYK (0.51) | GRM4AURKA | |
| SCHEMBL265776 | 0.80 | RAPGEF4 (0.56) | STK17ARAPGEF4KDRGRM4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628665-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2020-04-01 | — | — | EP | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2693881-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | STK17A 122/4885AXL 1/4885APP 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.